Our vision

Pharmaceutical innovation has accelerated, but the way of dosing medicines to patients has stayed the same. The demand for reinvented dosing is at an all-time high, and at OnDosis, we believe it is time that dosing of medicines catches up to the scientific advances of modern medicine. We’re about to make it happen.

Great potential for new ways to deliver medicine

  • Personalized medicine will drive the need for individualised dosing
  • Digital connectivity has the potential to revolutionize healthcare
  • Children & the elderly require tailored doses and simpler ways to take medicines
  • Society shares an increased concern over abuse of prescription drugs
  • Providers look for better ways of delivering and measuring outcomes

About the company

OnDosis proprietary technology delivers flexible and individualized dosing of oral medicines formulated as micro units. We are focused on providing reassurance in disease management, supporting adherence and providing greater convenience for patients. OnDosis is currently developing products for individualized dosing in diseases with a significant burden on patients and healthcare such as ADHD, pain management and immunosuppression for organ transplants. Hundreds of thousands of patients with these conditions could be helped by improved dosing, ultimately leading to improving health care outcomes.

The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often does not provide a good fit for the patient or treatment goal.

OnDosis was founded in 2017 and is headquartered in Gothenburg, Sweden, based on an idea that was spun-out from AstraZeneca, using technology based on development work initiated there. It was founded by GU Ventures and Martin Olovsson. OnDosis operates a network of strategic partners across all core functions including formulation and device development, IP, Regulatory and Business Development.

The flexibility of OnDosis technology provides the potential for application across several disease areas and patient segments where conventional tablets or capsules often does not provide a good fit for the patient or treatment goal.

OnDosis was founded in 2017 and is headquartered in Gothenburg, Sweden. The company is a spin-out from AstraZeneca, using technology based on development work initiated there. OnDosis operates a network of strategic partners across all core functions including formulation and device development, IP, Regulatory and Business Development.

Partner with us

OnDosis will partner with pharmaceutical companies based on co-development and license agreements. Our core technology will be developed specifically to fit medicines developed by the partner.

In addition, we will in select cases drive our own formulation development to be combined with the core technology as a fully developed combination medicine. We will target areas where the current standard of care is based on medicines that have lost exclusivity and where the unmet need is significant. In these cases, OnDosis will seek partnerships for commercialization.

We will develop our technology as a tool that enables faster and better clinical development, including novel approaches to dose finding and adaptive trial design, and capability to connect clinical results with patient behavior and engagement.

Management and board

Management team

Martin Olovsson

CEO and Co-founder

Martin cofounded OnDosis in 2017 based on a concept from AstraZeneca. He has solid experience from senior roles within the pharmaceutical industry across commercial and development at local, regional and global level. Martin has a past as Global lead for the Respiratory franchise in AstraZeneca and as CEO of the AstraZeneca Nordic-Baltic Region.

Stéphane Baronnet

Head of Product Development

Stéphane has 18 years of experience in product development. He has worked for the pharma and medtech industry and has vast experience in development of drug-device combinations and medical devices. Stéphane has held leadership and managerial positions with AstraZeneca.

Peter Wallich

Head of Business Development

Peter has worked in the pharmaceutical industry for over 30 years in Australia and Europe. He has worked in leadership positions in Global Marketing, Digital and Development in both AstraZeneca and Novartis.

Ulf Jonsson

Strategic Advisor

Ulf has 40 years of experience from the pharmaceutical industry, primarily within AstraZeneca. He has held senior, global positions covering areas such as pharmacokinetics, drug delivery, product development, portfolio management and business development. Ulf has extensive knowledge in the design and development of oral extended release formulations.

Tina Riesel

Head of Pharmaceutical development

Tina has worked with pharmaceutical product development for 25 years and within production responsible for new product introduction for 10 years. Her focus has been on solid modified release products, process technology, technology transfers and outsourcing. Tina also has vast knowledge in regulatory requirements and expectations for CMC documentation.

Board members

Staffan Ternström

Chairman of the board, CEO, Handicare

Staffan has a solid background as an accomplished commercial oriented leader in medical devices. He has worked as EVP Global Commercial and Strategy for Mölnlycke Healthcare and spent nearly 25 years in various positions within Johnson & Johnson including senior positions based in Belgium as well as in Sweden. He is currently also a board member in Ferrosan Medical Devices.

Kay Brickmann

Board member, Business development director, AstraZeneca

Kay is in his global role at AstraZeneca responsible for partnering and in- and out-licensing of cardiovascular, renal and metabolism assets in early clinical and pre-clinical development. He has almost 20 years of post-doctoral experience of R&D, global alliance management and business development roles at AstraZeneca. He is the author/co-author of 15 research papers and 13 patents.

Klementina Österberg

Board Member, CEO of GU Ventures

Klementina leads the University of Gothenburg’s holding company GU Ventures, that operates as an incubator and invests in the commercialization of innovations. She works actively with financing, start-ups and managing companies within the GU Ventures AB sphere. Previous assignments include the business plan competition, Venture Cup, various Volvo companies, Daimler Chrysler and Geveko Industries.

Jan Pilebjer

Board member, Business intelligence officer, GU Ventures

Jan has worked in major global companies and has founded and operated smaller start-up companies in both pharmaceuticals and medtech. Among his international and industrial experiences are management and marketing positions in Baxter Healthcare, Nycomed, KabiVitrum, Medirox, Biopool and Upjohn, where he had his base in countries such as Switzerland, the United States and Denmark.

Johan Öberg

Strategic advisor to the board

Johan has a solid background consulting in the health care industry globally on strategic, M&A as well as operational topics. He leads BCG’s global Private Equity Practice, advising on investments and value creation in multiple industries but with a focus in health care. He is also a core member of the firm’s Health Care as well as Corporate Development and Global Advantage practices. Johan has been involved in OnDosis from the strategy definition and business plan development.

Adina Welander

Strategic advisor to the board

Adina has a background as MD (leg. läk.) and earned her PhD in clinical epidemiology at the Karolinska Institute. Adina has broad experience from the MedTech and Pharmaceutical industries, as well as Payer and Provider organizations. She previously worked as senior project leader with the Boston Consulting Group, leading life science projects in Europe, US and the Middle East. She currently serves as Strategy Director at Elekta.

Partners

ALTEN, the European leader in engineering and technology consulting, provides support for its clients’ development strategies in the fields of innovation, R&D and it systems. ALTEN is active in over 20 countries. ALTEN Sweden has clients within Life Science, Energy, Telecom, Automotive, Defense & Aerospace and Industry.

alten.se

GU Ventures AB is fully owned by the Swedish government and is managed since 1998 by the University of Gothenburg. The mission is to commercialize ideas in connection to the operations at the University of Gothenburg and to deliver economic and social benefits, by investing funds in new businesses and supporting them through an incubator.

ventures.gu.se

AstraZeneca established the BioVentureHub in 2014 as an open innovation ecosystem to further strengthen competitiveness and dynamism in the Scandinavian life science industry. It is based on an innovative public-private partnership model and located at the heart of AstraZeneca Gothenburg.

azbioventurehub.com

Boston Consulting Group (BCG) is a global management consulting firm and the world’s leading advisor on business strategy. BCG partners with clients to identify their highest-value opportunities, address their most critical challenges, and transform their enterprises. Founded in 1963, BCG has offices in more than 90 cities in 50 countries.

bcg.com

Brandwork is a branding and design agency located in Gothenburg, delivering brand innovation to clients around the corner and worldwide. Brandwork was founded in 2005.

brandwork.se

Don’t miss a thing

Development is fast-moving at OnDosis. Sign up for our newsletter and we’ll make sure to keep you up to date with all our important news.